Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?

In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards. They will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:
- The SPC manufacturing waiver
- The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
- The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
- The General Court’s very recent Polpharma ruling on Data Exclusivity
Contact
Recommended articles
Kirian Claeyé promoted to partner at ALTIUS
ALTIUS is delighted to announce that Kirian Claeyé has been promoted to partner as per September 2023. Congratulations Kirian!
Read onThe Belgian Competition Authority has declared itself competent to examine mergers and acquisitions between hospitals under its merger control regime, following the Act of 29 March 2021
A lot of uncertainty has existed about the requirement for hospitals to notify M&A transactions to the Belgian Competition Authority (“BCA”). On 28 June 2023, the BCA decided to partially lift the stand-still obligation regarding a concentration between two hospitals, and it further clarified the applicable rules in a follow-up Communication of 14 July 2023.
Read onWEBINAR VIDEO | The New EU Deforestation Regulation: Stay Compliant, Succeed Sustainably
In this Life Sciences session, the experts from our agri-food law team Philippe de Jong and Bart Junior Bollen provided valuable insights into the Regulation's implications and equiped businesses with the necessary knowledge to ensure compliance in this evolving landscape.
Read on